Andrew W. Hahn, MD, Author at Grand Rounds in Urology

Andrew W. Hahn, MD

The University of Texas MD Anderson Cancer Center

Houston, Texas

Andrew W. Hahn, MD, is an Assistant Professor of Genitourinary Medical Oncology at the MD Anderson Cancer Center in Houston, Texas. Dr. Hahn’s research focus is to investigate how host factors influence response, resistance, and toxicity to cancer treatments and to design and run clinical trials to improve outcomes for patients with prostate and kidney cancer. His clinical focus is on prostate and kidney cancers.

Dr. Hahn earned a Bachelor of Arts in Synthetic Medicinal Chemistry and his Medical Doctorate at the University of Tennessee in Memphis. Dr. Hahn completed an internship and residency in Internal Medicine, and served as Chief Medicine Resident, at the University of Utah in Salt Lake City. Dr. Hahn then completed a fellowship in Medical Oncology at the MD Anderson Cancer Center.

Dr. Hahn has published over 50 articles and authored or co-authored 30 other editorials, reviews, and book chapters. He has been recognized for his contributions to the field, receiving numerous awards including, the American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Young Investigator and Career Development Awards, a Prostate Cancer Foundation Young Investigator Award, and a Department of Defense Early Investigator Research Award. Dr. Hahn is a member of the American Association for Cancer Research, American Society of Clinical Oncology, and the European Society for Medical Oncology.

Talks by Andrew W. Hahn, MD

PET Tumor Board – Case 4: A Case of a 66-year old Male with Elevated PSA of 9.06 and MRI Showing PI-RADS Category 4 and 5

E. David Crawford, MD, Wayne G. Brisbane, MD, Sean P. Collins MD, PhD, Sherief H. Gamie, MD, Daniel P. Petrylak, MD and Andrew W. Hahn, MD | Aug 2025

E. David Crawford, MD, and the panel discuss a case of a 66-year-old with elevated PSA, MRI PIRADS 5 lesion, and PSA density of 0.11.

Treating Oligometastatic Prostate Cancer in the PSMA PET Era

Andrew W. Hahn, MD | May 2025

Andrew W. Hahn, MD, addresses the treatment of oligometastatic prostate cancer in the PSMA PET era from a medical oncology perspective.

Panel Discussion: Molecular Targeted Imaging (MTI)

Christian P. Pavlovich, MD, David M. Albala, MD, Andrew W. Hahn, MD, Brian T. Helfand, MD, PhD, Ronald P. Kaufman, Jr., MD and A. Oliver Sartor, MD | May 2025

A panel discusses intermittent versus continuous androgen deprivation therapy (ADT) and its impact on prostate cancer outcomes.

Panel Discussion: TechCon: Novel and New Technologies in Prostate Cancer

David M. Albala, MD, Brian J. Davis, MD, PhD, Steven J. Frank, MD, FACR, FABS, FASTRO, Edwin M. Posadas, MD, FACP, Christian P. Pavlovich, MD and Andrew W. Hahn, MD | Mar 2025

A panel discusses advancements in prostate cancer treatment, particularly focusing on MRI-assisted radiosurgery.

Cardiometabolic Health for Men with Advanced Prostate Cancer: Lessons Learned and Future Directions

Andrew W. Hahn, MD | Sep 2024

Andrew W. Hahn, MD, addresses cardiometabolic health in men with advanced prostate cancer, focusing on the impacts of hormone therapy and strategies for managing cardiovascular risks.

In this 10-minute talk, Dr. Hahn highlights the common overlap of prostate cancer and cardiometabolic risk factors and underscores the necessity of evaluating cardiovascular risk in prostate cancer patients. He reviews data indicating that androgen deprivation therapy (ADT) can indirectly increase cardiovascular risks by altering body composition and intensifying metabolic syndrome. Adding androgen receptors nearly doubles cardiovascular event risk. Despite FDA advisories, guidelines, and the availability of cardiovascular risk assessments, many patients undergoing ADT lack appropriate cardiovascular monitoring.

Dr. Hahn highlights future directions in identifying men at heightened risk for cardiovascular events using imaging and genomic biomarkers. Promising approaches include myocardial perfusion PET scans and exploring genomic markers that correlate with cardiovascular toxicity in hormone therapy. Managing cardiometabolic health in advanced prostate cancer requires careful risk assessment and personalized approaches. Biomarkers are needed to effectively predict cardiovascular complications from hormone therapy.